Blockade of Endothelinergic Receptors Prevents Development of Proliferative Vitreoretinopathy in Mice

Maria Iribarne,* Liliana Ogawa,* Vanesa Torbidoni,* Cristian M. Dodds,† Ricardo A. Dodds,*† and Angela M. Suburo*

From the Facultad de Ciencias Biomédicas,* Universidad Austral, Pilar; and the Consultores Oftalmológicos,† Buenos Aires, Argentina

Proliferative vitreoretinopathy (PVR) is characterized by severe glial remodeling. Glial activation and proliferation that occur in brain diseases are modulated by endothelin-1 (ET-1) and its receptor B (ETR-B). Because retinal astrocytes contain ET-1 and express ETR-B, we studied the changes of these molecules in an experimental mouse model of PVR and in human PVR. Both ET-1 and ETR-B immunoreactivities increased in mouse retina after induction of PVR with dispase. Epiretinal and subretinal outgrowths also displayed these immunoreactivities in both human and experimental PVR. Additionally, myofibroblasts and other membranous cell types showed both ET-1 and ETR-B immunoreactivities. In early stages of experimentally induced PVR, prepro-ET-1 and ETR-B mRNA levels increased in the retina. These mRNA levels also increased after retinal detachment (RD) produced by subretinal injection. Treatment of mice with tezosentan, an antagonist of endothelinergic receptors, reduced the histopathological hallmarks of dispase-induced PVR: retinal folding, epiretinal outgrowth, and gliosis. Our findings in human and in dispase-induced PVR support the involvement of endothelinergic pathways in retinal glial activation and the phenotypic transformations that underlie the growth of membranes in this pathology. Elucidating these pathways further will help to develop pharmacological treatments to prevent PVR. In addition, the presence of ET-1 and ETR-B in human fibrous membranes suggests that similar treatments could be helpful after PVR has been established. (Am J Pathol 2008, 172:1030–1042; DOI: 10.2353/ajpath.2008.070605; DOI: 10.2353/ajpath.2008.070605)
Müller glial cells of normal BALB/c mice, although we have found ETR-B in these cells after light injury.15,24 Other authors have reported the presence of ETR-B immunoreactivity in normal Müller cells of C57BL/6 mice and pigs.22,25 ETR-B is also normally present in horizontal cells,24 another participant in the retinal PVR response.4 To investigate involvement of endothelinergic pathways in PVR, we explored ET-1 and ETR-B immunoreactivities in experimentally induced murine PVR,7 and human surgical specimens. Then we tested the effects of tezosentan, a blocker of endothelinergic receptors, on development of PVR-like lesions in mice.

Materials and Methods

PVR and RD Lesions in Mice

Experimental procedures were performed in male C57BL/6 mice (6 to 8 weeks old), following the Association for Research in Vision and Ophthalmology Statement for the Use of Animals. They were anesthetized with chloral hydrate (400 mg/kg, i.p.) and received one drop of 0.5% propacaraine (Alcon, Buenos Aires, Argentina) for local anesthesia. One drop of 5% phenylephrine and 1% tropicamide (Poen, Buenos Aires, Argentina) was applied for iris dilatation and eyes were covered with 0.25% carbomere (carboxypolymethylene) drops (Latlas; Atlas, Buenos Aires, Argentina). PVR-like lesions were induced as previously described,7 using 0.2 or 0.3 U/ml of dispase (Sigma-Aldrich, St. Louis MO). Fundus examinations were made in anesthetized animals with iris dilatation. Alternatively, hyaluronic acid (Hyalosol; Bausch and Lomb, Buenos Aires, Argentina) was slowly injected through a 30-gauge needle, inserted below the limbus, until a detachment covering the dorsal quadrant could be observed. Procedures were performed at 8 p.m.25 Animals were euthanatized 1 week after detachment. Membranes did not develop in this model.

Human PVR Membranes

Human specimens (n = 54, 40 epiretinal and 14 subretinal) were obtained from patients undergoing surgery for PVR. Use of human tissues adhered to World Medical Association Declaration of Helsinki and was approved by our Institutional Research Board.

Immunohistochemical Detection of Endothelinergic, Glial, and Smooth Muscle Markers

Human PVR membranes were flattened on a sterilized Millipore filter (Millipore, Billerica, MA) and immersed in a fixative mixture containing paraformaldehyde and picric acid in phosphate buffer.27 Mice were deeply anesthetized (chloral hydrate, 800 mg/kg) and fixed by intracardiac perfusion with 4% paraformaldehyde in 0.1 mol/L phosphate buffer, pH 7.3. Specimens were cryoprotected28 and frozen in N2-cooled acetone. Sections (14 μm) were stained with Neutral Red or incubated with primary antibodies (Table 1).

Table 1. Primary Antibodies Used in This Study

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Source</th>
<th>From</th>
</tr>
</thead>
<tbody>
<tr>
<td>ET-1</td>
<td>Rabbit polyclonal</td>
<td>Peninsula Laboratories, Belmont, CA</td>
</tr>
<tr>
<td>ETR-B</td>
<td>Rabbit polyclonal</td>
<td>Alomone Labs, Jerusalem, Israel</td>
</tr>
<tr>
<td>pGFAP</td>
<td>Rabbit polyclonal</td>
<td>DAKO Labs, Carpenteria, CA</td>
</tr>
<tr>
<td>mGFAP</td>
<td>Mouse monoclonal</td>
<td>Bio Genex, San Ramon, CA</td>
</tr>
<tr>
<td>mGFAP-Cy-3 conjugate</td>
<td>Mouse monoclonal</td>
<td>Sigma-Aldrich, St. Louis, MO</td>
</tr>
<tr>
<td>Glutamine synthase</td>
<td>Rabbit polyclonal</td>
<td>Dr. A. Marmorstein, University of Arizona College of Medicine, Tucson, AZ</td>
</tr>
<tr>
<td>Cellular retinaldehyde binding protein (CRALBP)</td>
<td>Mouse monoclonal</td>
<td>Dr. J.C. Saari, University of Washington, Seattle, WA</td>
</tr>
<tr>
<td>Smooth muscle actin</td>
<td>Mouse monoclonal</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>mSMA-Cy3 conjugate</td>
<td>Mouse monoclonal</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Opsin</td>
<td>Sheep polyclonal</td>
<td>Dr. D.S. Papermaster, University of Connecticut Health Center, Farmington, CT</td>
</tr>
<tr>
<td>Glutamine synthase</td>
<td>Rabbit polyclonal</td>
<td>Dr. A. Marmorstein, University of Arizona College of Medicine, Tucson, AZ</td>
</tr>
<tr>
<td>Cellular retinaldehyde binding protein (CRALBP)</td>
<td>Mouse monoclonal</td>
<td>Dr. J.C. Saari, University of Washington, Seattle, WA</td>
</tr>
<tr>
<td>Smooth muscle actin</td>
<td>Mouse monoclonal</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>mSMA-Cy3 conjugate</td>
<td>Mouse monoclonal</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Opsin</td>
<td>Sheep polyclonal</td>
<td>Dr. D.S. Papermaster, University of Connecticut Health Center, Farmington, CT</td>
</tr>
</tbody>
</table>

Optic projections and merged images were produced
with the Confocal Assistant Software (Bio-Rad). To facilitate comparisons, endothelinergic molecules, smooth muscle actin (SMA), and GFAP were artificially colored in green, red, and blue, respectively.

**Pharmacological Treatment**

One hour after RD or dispase injection (0.3 U/μl), mice were randomly separated in two groups. Experimental mice received tezosentan (10 mg/kg, s.c., Actelion Pharmaceuticals, Zurich, Switzerland), a dual ET receptor antagonist,30 and control mice received saline. Injections were repeated daily and mice were euthanized after 7 days of treatment. Retinas were fixed for immunohistochemistry or freshly dissected for GFAP Western blots.

**Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis**

Retinal homogenates were prepared 3 days after RD or intravitreal dispase injection (n = 4 for each condition). Total RNA was extracted using RNeasy lipid tissue mini kit (Qiagen, Valencia, CA). RNA integrity was assessed by electrophoresis on a 1% agarose gel. Two μg of RNA was reverse-transcribed into cDNA with SuperScript II reverse transcriptase kit (Invitrogen, Carlsbad, CA) and oligo (dT) primers, following the manufacturer’s recommendations. Each set of reactions always included a no-sample negative control.

Amplification of cDNA for preproET-1, ETR-B, and GAPDH as internal standard was performed with 35 PCR cycles (melting at 94°C for 30 seconds, annealing at 58°C for 30 seconds, extension at 72°C for 1 minute), using Platinum TaqDNA polymerase (Invitrogen). Trials were made to select the appropriate number of cycles so that amplification was in the exponential range and had not reached a plateau. The following specific primers were used: preproET-1 sense 5’-AGCTGTTGGAAGAAGGAAAGGAAACTACG-3’ and preproET-1 antisense 5’-GACAGTGACAAAGGTGAGGTAGTACT-3’; ETR-B sense 5’-GGCT-AGTGTGTTTTCAGAGGCTTG-3’ and ETR-B antisense 5’-CAGAACCAGACACCCACAAAT-3’; GAPDH sense 5’-ACCACGTCATGCCATCACA-3’ and GAPDH antisense 5’-TCCACACCCTGTGTTGTA-3’. PCR products were analyzed by electrophoresis on a 1% agarose gel and the expected sizes of amplicons were 728 bp for preproET-1, 822 bp for ETR-B, and 452 bp for GAPDH.

**Quantitative Evaluation of Retinal Folding and Membrane Growth**

Eyes were sectioned serially. Every third section (~24 to 26 sections per eye) was incubated with the polyclonal GFAP antiserum and developed with the immunoenzymatic procedure. To compare the severity of dispase-induced lesions, each section was examined by a blinded observer who determined the presence or absence of retinal folds, epiretinal membrane, 1 or 2 for membranes larger than half retina); presence of subretinal membranes, 1. The total score for each eye divided by the number of sections gave an average score reflecting the presence and extension of lesions in each eye. Comparisons were made with two-way analysis of variance with Bonferroni posttests (GraphPad Prism version 4.00 for Windows; GraphPad Software, San Diego, CA).

**GFAP Western Blot Analysis**

Retinas (two per sample) were homogenized in an extraction buffer containing 10 mmol/L Tris-HCl with 2 mmol/L ethylenediaminetetraacetic acid, 150 mmol/L NaCl, 1% Triton X-100, and protease inhibitor cocktail (Sigma-Aldrich). Extracts (30 μg of protein per lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred (100 V, 90 minutes) onto a nitrocellulose filter using standard techniques. Equal sample loading for electrophoresis was confirmed by the Bradford protein assay (Bio-Rad). A monoclonal antibody to GFAP from Covance (Indianapolis, IN) was used at a dilution of 1:1000. Immunoblotting was performed with mGFAP antibody. The membrane was further incubated with biotinylated anti-mouse IgG and extravidin-alkaline phosphatase. Colorimetric detection of alkaline phosphatase was made with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium (Sigma-Aldrich). Optical density was estimated using Scion Image β 4.02 Win software (Scion Corp., Frederick, MD). Analysis of variance and t-test for paired samples were used for statistical comparisons (GraphPad Prism version 4.00 for Windows).

**Results**

**Dispase-Induced PVR**

We have previously shown7 that mice receiving intravitreal dispase (0.2 U/μl) gradually develop a PVR-like condition. Retinal folds appear during the first and second weeks after injection whereas epiretinal membranes appear after the second week in ~60 percent of the injected eyes. Therefore, we evaluated distribution of ET-1 and GFAP immunoreactivity 7, 14, or 21 days after intravitreal injection (n = 10 for each stage). Control C57BL/6 mice showed the same pattern of ET-1, ETR-B, and GFAP immunoreactivities previously described in BALB/c mice.15 Astrocytes displayed strong ET-1 and GFAP immunoreactivity, whereas normal Müller cells lacked ET-1 and GFAP immunoreactivity (Figure 1, A and B).

**Retinal Folding and Outgrowths**

After dispase injection, a thick layer of ET-1- and GFAP-immunoreactive processes appeared along the vitreal surface. Similar processes extended into deeper layers of the retina, usually following an irregular course (Figure 1, C and D). They could perhaps correspond to in-growing astrocyte branches because they were not labeled by typical Müller cell markers, such as CRALBP...
Figure 1. Consecutive sections of mouse retina immunoenzymatically stained with antibodies against ET-1 (left) and GFAP (right). The retinal vitreal surface is always shown at the top of the micrographs. A and B: In the normal retina, ET-1 immunoreactivity was only found in astrocytes sparsely distributed along the vitreal surface. GFAP immunostaining labeled similar cell bodies and processes. C and D: These and following images correspond to 0.2 U/µl dispase-injected eyes. One week after injection, the vitreal surface was completely covered by ET-1-immunoreactive astrocyte cell bodies and processes. Irregular ET-1-immunoreactive processes, following a nonradial course, extended into outer layers of the retina (white arrows). GFAP immunolabeled structures along the vitreal surface included astrocytes and Müller endfeet (white arrowhead). Notice the large number of GFAP-immunoreactive processes extending to the outer retinal layers. Most of them followed the typical radial course of Müller cells, but a few resembled endothelinergic processes (white arrows). E and F: Illustration of an inner retinal fold bridged by a small outgrowth (arrows), appearing a week after dispase injection. Strong ET-1 and GFAP immunoreactivities appeared along the vitreal border, within the outgrowth and in retinal processes. GFAP revealed a larger number of processes than ET-1. Immunostained glial cells also surrounded a blood vessel (b). G and H: Retina sections (2 weeks after dispase) showing an outer fold (f). A thin cellular membrane (arrows) attached to the vitreal surface exhibited strong ET-1 and GFAP immunostaining. Elongate ET-1- and GFAP-immunoreactive cells were accumulated along the retinal vitreal surface (asterisk). Immunoreactive processes extended across the retina: few endothelinergic processes reached the invaginated ONL, whereas numerous GFAP-immunoreactive processes appeared close to the subretinal folded surface. Scale bar: 50 μm (A–E, G, H), 25 μm (F).
and GS antibodies (not shown). By contrast, most GFAP-immunoreactive processes followed the typical radial course of Müller glia and lacked ET-1 immunoreactivity.

Retinal folds appeared before RD or membrane development. Inner folds showed strong ET-1 and GFAP immunostaining of vitreal glial structures (Figure 1, E and F). Outer folds presented as invaginations of outer retinal layers with a small detachment restricted to the base of the folding (Figure 1, G and H). Vitreal outgrowths appeared 1 or more weeks after dispase injection. They usually attached to disrupted regions of the inner limiting membrane (ILM) and included ET-1- and GFAP-immunoreactive cells (Figure 1, E–H).

Epi- and subretinal fibrous membranes were usually observed at later stages. ET-1-immunofluorescent structures occupied the boundary between retina and epiretinal membranes, and also appeared within the retina (Figure 2).
Subretinal outgrowths also contained ET-1-immunoreactive cells. In fibrous membranes, SMA-immunoreactive cells often showed ET-1 immunostaining (Figure 2C). GFAP-immunoreactive cells were also present, but they seldom displayed ET-1 labeling (not shown).

**ETR-B Immunoreactivity**

In control retinas, weak ETR-B immunoreactivity was only found in astrocytes (see below). After dispase injection, stronger ETR-B immunoreactivity appeared in astrocytes lying along folded vitreal surfaces (Figure 2D). Most retinal structures also showed GFAP immunoreactivity, suggesting a relationship with astrocytes or Müller cells. Epiretinal processes (Figure 2, D and E) also showed ETR-B immunoreactivity, but only a fraction of them also displayed GFAP immunoreactivity. Widespread immunostaining of cell nuclei hindered identification of cells with selective cytoplasmic localization of ETR-B immunofluorescence. Although mouse fibrous membranes contained ETR-B-immunofluorescent cells, we could not demonstrate its co-localization with SMA immunoreactivity.

**Human Specimens**

**Retina**

A few surgical specimens (n = 4) contained small patches of retinal tissue. These fragments always showed histoarchitectural disorganization, but Nomarski optics or staining with Neutral Red allowed recognition of retinal layering. Opsin immunoreactivity identified photoreceptor outer segments (not shown). Some fragments showed a thin layer of ET-1-immunoreactive cells along the vitreous surface, whereas other fragments displayed this immunoreactivity in more extensive areas (Figures 3A and 4A). GFAP immunoreactivity occupied the same regions and often co-localized with ET-1 immunoreactivity. The regular GFAP-immunoreactive pattern of the ILM disappeared at sites of membranous outgrowth attachment to the retinal vitreal surface. Membranous outgrowths showed both ET-1 and GFAP immunoreactivity (Figures 3 and 4A).

**Membranes**

Fibrous and nonfibrous regions differed in amount of extracellular matrix. Nonfibrous regions of epi- and subretinal membranes contained many ET-1- and GFAP-immunoreactive cells but few SMA-immunolabeled cells. Fibrous regions contained numerous ET-1- and SMA-immunoreactive cells. Co-localization proved that these cells were endothelinergic myofibroblasts (Figure 4B). By contrast, we could not detect co-localization of ET-1 and GFAP immunoreactivities in fibrous membranes. Neither did we find examples of co-localization of ET-1 and CRALBP or GS immunofluorescence. Human PVR membranes also contained many ETR-B-immunoreactive cells. They often showed an elongate phenotype arranged in regular layers (Figure 4, C–G). SMA-immunoreactive myofibroblasts with and without ETR-B immunoreactivity were present in the same membrane (Figure 4, E–G). By contrast, human fibrous membranes seldom contained cells displaying both ETR-B and GFAP immunofluorescence (Figure 4H). No significant differences were detected between epi- and subretinal membranes.

**Blockade of ET Receptors and Development of PVR-Like Lesions**

Testing showed that intravitreal injection of 0.3 U/µl dispase in mice 8 weeks old (or younger) induced membrane growth in every eye after just 1 week. Therefore, we used this procedure to evaluate the effects of tezosentan. In animals receiving saline, all specimens had large RDs. Their retinas showed inner and outer retinal folds, and had

---

**Figure 3.** Sections through a retinal fragment embedded in a human PVR specimen labeled with the immunoenzymatic method and examined under Nomarski optics. A: ET-1 immunoreactivity appeared along the vitreal surface of a highly disorganized retinal fragment. An epiretinal outgrowth (asterisk) separated from the inner retinal surface also showed strong ET-1 immunoreactivity. B: A section through the same fragment (not consecutive) showed extensive GFAP immunoreactivity in most retinal layers. GFAP-immunoreactive cells were present in an outgrowth (asterisk) apparently emerging from the retinal surface. A neighboring outgrowth (asterisks) had no immunoreactivity. Scale bar: 50 µm.
Figure 4. ET-1- and ETR-B-immunoreactive cells in human specimens. A: Confocal images through a retinal fragment embedded in a human epiretinal membrane showed an epiretinal outgrowth (asterisk) displaying strong ET-1 immunoreactivity. ET-1-immunoreactive cells followed radial pathways across the retina (arrowheads) or coursed along its vitreal surface (v). GFAP immunofluorescence essentially labeled the same structures. However, some GFAP-immunoreactive cells lacked ET-1 immunofluorescence. B: Confocal images of a fibrous human epiretinal membrane showing elongate cells arrayed in parallel layers. These cells displayed both ET-1 and SMA immunofluorescence as demonstrated in the merged image. C: The immunoenzymatic procedure demonstrated elongate ETR-B-labeled arrayed in parallel layers. D: This view of a fibrous membrane showed a long ETR-B-immunoreactive cell parallel to the surface of the membrane. The membrane contained abundant pigmented granules. E: Confocal images of a fibrous membrane showed a layer of ETR-B cells. A different cell layer displayed GFAP immunofluorescence. Both layers had SMA immunoreactivity. ETR-B co-localized with SMA in cells of the first layer (right). In the second layer, GFAP immunofluorescence was segregated from SMA. F: Elongate cells displayed ETR-B immunofluorescence. SMA immunoreactivity appeared in cells of similar shape. However, no co-localization could be detected in these cells. G: Another membrane showed a large cluster of ETR-B-immunoreactive cells. The same cells also displayed SMA immunofluorescence. However, a neighboring group of SMA-immunoreactive cells (left) was not labeled by ETR-B. H: An isolated cell displaying ETR-B immunofluorescence also showed GFAP immunoreactivity. Merge demonstrates co-localization. Scale bars: 25 μm (A, C, E–G), 50 μm (B), 15 μm (D, H).
epi- and subretinal membranes. By contrast, retinal folding and membrane growth were minimal in animals receiving tezosentan (Figure 5), although some of these retinas exhibited large detachments. Quantitative analysis of these features (Table 2) indicated that tezosentan treatment significantly reduced the scores for folds \( P < 0.01 \) and epiretinal membranes \( P < 0.01 \). Decrease of subretinal membranes was not statistically significant. Remarkably, subretinal membranes did not contain ETB-R immunoreactivity whereas ETB-R-immunoreactive cells were found within epiretinal membranes and along the boundary between these membranes and the retina (Figure 6).

Comparison of GFAP immunostaining in tezosentan- and saline-treated animals suggested a decrease of retinal gliosis. Western blots showed a trend toward lower GFAP levels in tezosentan-treated mice. However, differences were not statistically significant (Figure 7), probably because high GFAP immunostaining was still found in regions of detachment and subretinal membranes. Because downregulation of GFAP could be one of the factors decreasing retinal folding, we measured GFAP protein in retinas detached by subretinal injections of hyaluronic acid. These retinas expressed higher GFAP levels than those subjected to dispase injection. Mice receiving tezosentan after RD had ∼50% of the GFAP levels found in saline-treated mice (Figure 7).

**Table 2.** PVR Lesions after Treatment with Tezosentan

<table>
<thead>
<tr>
<th>Lesions</th>
<th>Saline</th>
<th>Tezosentan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinal folds</td>
<td>0.73 ± 0.13</td>
<td>0.14 ± 0.07</td>
</tr>
<tr>
<td>Epiretinal membranes</td>
<td>0.78 ± 0.22</td>
<td>0.10 ± 0.07</td>
</tr>
<tr>
<td>Subretinal membranes</td>
<td>0.62 ± 0.13</td>
<td>0.41 ± 0.14</td>
</tr>
</tbody>
</table>

Dispase-induced lesions in eyes from saline- or tezosentan-treated animals scored in GFAP-immunostained sections as described in the Materials and Methods. Values represent the average for seven eyes (from five animals) ± SEM. Two-way analysis of variance indicated that the effect of treatment was highly significant \( P = 0.0001 \). Bonferroni post-tests indicated that scores for retinal folds and epiretinal membranes were statistically significant, \( P < 0.01 \) and \( P < 0.05 \), respectively.

**Figure 5.** A: These low-magnification montages of GFAP-immunostained retinal cryosections show the effect of tezosentan treatment on retinal lesions appearing 1 week after 0.3 U/μl dispase injection. The retina from an untreated mouse (left) displayed severe folding. Arrows point to epiretinal membranes. Large areas of the inner retina displayed strong GFAP immunoreactivity. The retina from a mouse receiving tezosentan (right) had no folds. The vitreal surface showed increased GFAP immunoreactivity. GFAP immunostaining of the inner retina was only found at a small region of the retina. B: Outer retinal folds (f) and an epiretinal membrane were present in this untreated retina. GFAP-immunoreactive structures form a thick layer along the vitreal surface and extend toward the outer retina. The arrowhead points to a GFAP-immunoreactive vitreal outgrowth. C: This retina from a treated animal appeared well attached to the RPE and showed good preservation of retinal layering. GFAP-immunoreactive structures were restricted to the vitreal surface. Scale bars: 200 μm (A); 60 μm (B, C).

**Figure 6.** ET-1 immunoreactivity in mouse epi- and subretinal membranes developing 1 week after 0.3 U/μl dispase injection. A: This epiretinal membrane (m) was attached to the retinal surface and exhibited numerous ETB-1-immunoreactive cells. v, vitreal space; r, retina. B: A subretinal membrane (m), lodged between the retina (r) and the choroid (c), lacked ETB-1 immunostaining. Scale bars: 50 μm (A); 100 μm (B).

Early Changes of ET-1 and ETR-B after Dispase Intravitreal Injection or RD

Because endothelinergic activation and glial transformation should precede development of epi- or subretinal outgrowths, we also evaluated early stages of murine PVR. RT-PCR showed that prepro-ET-1 and ETR-B mRNAs highly increased 3 days after 0.3 U/μl dispase injection (Figure 8), before membranous outgrowths
could be detected. An increase was also found after experimental RD, a condition followed by spontaneous reattachment without membrane development.

Immunohistochemistry (n = 4 for each group) showed the presence of retinal folds 3 days after dispase injection (0.3 U/μl). Astrocytes showed strong ET-1 and ETR-B immunolabeling. They had thick processes that often extended into the vitreal cavity, suggesting early disruption of the ILM (Figure 9, A and B, E and F). No folds were observed after RD. Astrocytes displaying strong ET-1 immunolabeling were more often found in control retinas (Figure 9, C and D). ETR-B immunoreactivity strikingly increased in astrocytes and, in some retinal regions, also in Müller cells (Figure 8, G and H). Evidence of ILM disruption was not found in RD specimens.

Discussion

Our findings in human and experimental PVR showed the presence of cells expressing ET-1 and ETR-B in these lesions. An involvement of endothelinergic pathways in development of PVR is supported by prevention of retinal folding and growth of epiretinal membranes in mice treated with tezosentan, a mixed antagonist of endothelinergic receptors.

Endothelinergic Cells, Endothelinergic Receptors, and Development of PVR

Among normal retinal cells of BALB/c mice, astrocytes present the highest ET-1 immunoreactivity.15 These observations have now been confirmed in C57BL/6 mice.

ET-1 immunoreactivity in astrocytes and their processes increased after PVR-like lesions induced by 0.2 and 0.3 U/μl dispase intravitreal injection, and after RD produced by hyaluronic acid subretinal injection. In PVR-like lesions, astrocytes also displayed an abnormally high number of cell processes. These processes extended into the vitreal cavity when disruption of the ILM was present. This is not surprising, because astrocytes migrating through focal interruptions in the ILM were identified in early descriptions of massive periretinal proliferation.33

Three days after intravitreal dispase injection, astrocytes showed a large increase in ET-1 and ETR-B immunoreactivity that was accompanied by prepro-ET-1 and ETR-B mRNA up-regulation in the retina. The simultaneous increase of ET-1 and ETR-B suggests that astrocytes would be activated by an autocrine mechanism. Extension of astrocytic processes into the vitreal cavity would be the first step in epiretinal membrane development. Prevention of retinal folding and epiretinal membrane growth by the endothelinergic antagonist tezosentan would then be explained by blockade of these autocrine mechanisms. Subretinal membrane growth would still be possible because they lacked ETR-B, at least in the dispase model. Further studies with selective antagonists are required to understand the role of each endothelinergic receptor in PVR. Although we have not observed glial ETR-A in the retina,15,24 co-existence of both receptors has been reported in brain astrocytes in vitro.34 In addition, some endothelinergic effects on astrocytes and fibroblasts require the simultaneous participation of both receptors.35,36

A Model to Explain Endothelinergic Involvement in Retinal Folding and Membrane Growth

ET-1 immunoreactive astrocytes appear in mechanically deformed regions of the brain. In addition, stretching astrocyte cultures causes an increase in ET-1 production and secretion into the culture media.37,38 Most brain astrocytes do not express ET-1 under normal conditions. By contrast, retinal astrocytes always show strong ET-1 immunoreactivity, even in the absence of injury. Because
Figure 9. Immunoreactivity of ET-1 (left) and ETR-B (right) was demonstrated by the immunoenzymatic procedure 3 days after RD or dispase injection (0.3 U/ml). Images were acquired with Nomarski optics. A: This high-power view, corresponding to a normal retina, showed that isolated astrocytic processes were present. B: A retinal fold induced by dispase injection, showed numerous ET-1-immunostained astrocytes. The ILM had disappeared and astrocyte processes invaded the vitreal space. The inset illustrates the large size of these astrocytes. C and D: Low- and high-power views of ET-1 immunoreactivity after RD. ET-1 was moderately increased and could only be detected in astrocytes. E: This high-power view showed weak ETR-B immunoreactivity in astrocytic processes of control retinas. F: After dispase injection, numerous ETR-B-immunoreactive astrocytes appeared along the vitreal surface of the retina. In regions of ILM disruption, numerous astrocytic processes extended into the vitreal space. G and H: These images correspond to detached retinas. Notice the preservation of the ILM in both examples. G shows perivascular astrocytes displaying strong ETR-B immunoreactivity. H shows a retinal region displaying ETR-B immunoreactivity in astrocytes and Müller cells. Cell nuclei were also strongly immunostained in these preparations. Scale bars: 15 μm (A, B (inset), D, E, F (inset)); 25 μm (B, F–H); 50 μm (C).
Epi- and Subretinal Membranes

Epi- and subretinal membranes contained ET-1-immunoreactive cells. Some ET-1-immunoreactive cells also showed GFAP immunoreactivity. These cells were usually placed in early vitreal outgrowths or boundaries between retina and epiretinal membrane. By contrast, in fibrous regions, ET-1 immunoreactivity often co-localized with SMA immunoreactivity. Transformation of astrocytes in myofibroblasts is a likely possibility. SMA has been previously detected in astrocytes, whereas loss of GFAP immunoreactivity has been reported after myofibroblast transformation of porcine Müller cells in vitro. Myofibroblasts could also arise from other cells involved in PVR development, such as macrophages and retinal pigment epithelial cells that also can express ET-1.

PVR membranes also included ETR-B-immunoreactive cells. In human membranes, a fraction of these cells corresponded to a subpopulation of myofibroblasts. In mice, co-localization of ETR-B with GFAP or SMA was seldom found. Thus, more studies are needed to identify the phenotypical identity of membranous ETR-B-immunoreactive cells. This could be of therapeutic importance, because endothelinergic blockade might also be effective in the prevention of fibrosis and tractional RD.

The importance of ETR-B receptors for membrane growth is also reflected by persistence of mouse subretinal membranes, which had no detectable ETR-B immunoreactivity, after treatment with tezosentan. Differences between epi- and subretinal membrane are well known. In the mouse dispase model, only subretinal membranes contain RPE cells. However, human subretinal membranes had ETR-B-immunoreactive cells, suggesting that cells within these membranes could differentiate into this phenotype. Alternatively, the RPE could release chemotactants for astrocytes.

Conclusions

Our findings support the involvement of ET receptors in development of PVR typical lesions, namely, glial activation, retinal folding, and membrane growth. Further studies are needed to understand the importance of different retinal autocrine and paracrine loops, as well as the contribution of each ET isoform to PVR pathogenesis. Answering these questions will help to develop pharmacological treatments preventing PVR development, particularly in high-risk cases. In addition, the presence of ET-1 and ETR-B in human fibrous membranes suggests that similar treatments could be helpful after PVR has been established.

Acknowledgments

We thank Guillermo Gastón, Germán Ruffolo, Silvina Ruffolo, and Soledad Arregui for their skillful technical assistance.

References

6. Guérin CJ, Anderson DH, Fisher SK: Changes in intermediate filament...
51. Egnczyk GF, Pomeris JD, Schmidt JA, Rogers SD, Peters C, Ghilard JD, Mantyh PW, Maggio JE: Proteomic analysis of the reactive phenotype of astrocytes following endothelin-1 exposure. Pro- teomics 2003, 3:689–698
53. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, Black CM, Abraham DJ: Endothelin-1 promotes myofibrolastic induc- tion through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contrac-
tile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, 15:2707–2719


52. Gamulescu MA, Chen Y, He S, Spee C, Jin M, Ryan SJ, Hinton DR: Transforming growth factor beta2-induced myofibroblastic differenti-


